◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Biocon Limited (BIOCON)
公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Healthcare · ウォール街（米国） · 最終更新: 2026-09-20
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments.
主要指標
- 時価総額: ₹627 billion
- 売上高（2026-03-31 期末の会計年度）: ₹167.8B
- 当期純利益: ₹3.9B
- 売上総利益率: 66.1%
- 純利益率: 2.3%
インタラクティブチャートと全財務諸表を見る →
年次損益計算書
| 損益計算書 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|
| 売上高合計 | ₹167.8B | ₹150.5B | ₹142.0B | ₹109.3B |
| 売上総利益 | ₹110.9B | ₹98.5B | ₹92.9B | ₹72.7B |
| 営業利益（EBIT） | ₹17.2B | ₹16.3B | ₹14.3B | ₹16.3B |
| 当期純利益 | ₹3.9B | ₹10.1B | ₹10.2B | ₹4.6B |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は BIOCON のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/BIOCON
類似企業
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.